Total Payments
$63,904
2024 Payments
$3,900
Companies
89
Transactions
1,293
Medicare Patients
23,989
Medicare Billing
$10.2M
Payment Breakdown by Category
Research$29,801 (46.6%)
Food & Beverage$26,015 (40.7%)
Other$7,701 (12.1%)
Education$386.60 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $29,801 | 6 | 46.6% |
| Food and Beverage | $26,015 | 1,257 | 40.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,701 | 8 | 12.1% |
| Education | $386.60 | 22 | 0.6% |
Payments by Type
General
$34,103
1,287 transactions
Research
$29,801
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $30,768 | 70 | $0 (2024) |
| F. Hoffmann-La Roche AG | $7,701 | 8 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $2,439 | 144 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,932 | 118 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,527 | 74 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,526 | 46 | $0 (2024) |
| Incyte Corporation | $1,327 | 47 | $0 (2024) |
| Janssen Biotech, Inc. | $1,044 | 66 | $0 (2024) |
| Genentech USA, Inc. | $984.96 | 58 | $0 (2024) |
| Amgen Inc. | $964.50 | 55 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,900 | 190 | AstraZeneca Pharmaceuticals LP ($403.88) |
| 2023 | $3,416 | 129 | Seagen Inc. ($662.40) |
| 2022 | $3,529 | 160 | Novartis Pharmaceuticals Corporation ($354.48) |
| 2021 | $2,905 | 116 | Incyte Corporation ($238.43) |
| 2020 | $2,078 | 97 | AstraZeneca Pharmaceuticals LP ($301.26) |
| 2019 | $15,783 | 185 | Celgene Corporation ($6,221) |
| 2018 | $12,044 | 231 | Celgene Corporation ($6,179) |
| 2017 | $20,249 | 185 | Celgene Corporation ($17,682) |
All Payment Transactions
1,293 individual payment records from CMS Open Payments — Page 1 of 52
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $33.45 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/18/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: Oncology | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $6.01 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/12/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Oncology | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: Oncology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.56 | General |
| Category: Oncology | ||||||
| 12/10/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug), TGCT | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.52 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $22.31 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: Oncology | ||||||
| 11/25/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: DESMOID TUMORS | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: Oncology | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $23.16 | General |
| Category: Oncology | ||||||
| 11/13/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/13/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $6.39 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $3.36 | General |
| Category: Oncology | ||||||
| 11/12/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $21.65 | General |
| Category: Hematology/Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABI-007-NSCL-003 | Celgene Corporation | $17,572 | 2 |
| A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction with nab-Paclitaxel Plus Carboplatin in subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC) (ABI-007-NSCL-003) | Celgene Corporation | $6,194 | 2 |
| ABI-007-NSCL-003 - A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction with nab-Paclitaxel Plus Carboplatin in su | Celgene Corporation | $4,511 | 1 |
| ABI-007-NSCL-006 - A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Im | Celgene Corporation | $1,524 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 45 | 3,891 | 118,427 | $6.0M | $1.7M |
| 2022 | 68 | 5,387 | 174,797 | $8.2M | $2.4M |
| 2021 | 78 | 6,482 | 212,424 | $8.8M | $2.7M |
| 2020 | 98 | 8,229 | 307,233 | $11.1M | $3.5M |
Total Patients
23,989
Total Services
812,881
Medicare Billing
$10.2M
Procedure Codes
289
All Medicare Procedures & Services
289 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 26 | 21,400 | $2.9M | $827,228 | 28.2% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 17 | 7,568 | $817,344 | $270,649 | 33.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 60 | 11,220 | $572,220 | $206,145 | 36.0% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 59 | 16,100 | $370,300 | $94,717 | 25.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 440 | 942 | $225,138 | $61,329 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 218 | 579 | $196,281 | $57,901 | 29.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 130 | 417 | $157,626 | $40,162 | 25.5% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 12 | 1,400 | $79,800 | $22,869 | 28.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 822 | 2,294 | $66,526 | $17,333 | 26.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 791 | 2,016 | $18,144 | $16,934 | 93.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 106 | 233 | $44,037 | $11,195 | 25.4% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 29 | 7,670 | $38,350 | $10,506 | 27.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 214 | 768 | $52,992 | $8,152 | 15.4% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 13 | 53 | $29,786 | $6,813 | 22.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 22 | 17,340 | $69,360 | $6,772 | 9.8% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 17 | 40 | $25,480 | $5,592 | 21.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $17,214 | $5,174 | 30.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 97 | 425 | $25,925 | $5,101 | 19.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 47 | 198 | $15,642 | $4,308 | 27.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 50 | 50 | $14,900 | $3,684 | 24.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 31 | 69 | $12,282 | $3,404 | 27.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 17 | 59 | $12,154 | $3,391 | 27.9% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 13 | 18,000 | $36,000 | $2,988 | 8.3% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 24 | 172 | $9,632 | $2,723 | 28.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 58 | 123 | $10,332 | $2,695 | 26.1% |
About Dr. Michael Mccleod, DO
Dr. Michael Mccleod, DO is a Medical Oncology healthcare provider based in Fort Myers, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1316920259.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Mccleod, DO has received a total of $63,904 in payments from pharmaceutical and medical device companies, with $3,900 received in 2024. These payments were reported across 1,293 transactions from 89 companies. The most common payment nature is "" ($29,801).
As a Medicare-enrolled provider, Mccleod has provided services to 23,989 Medicare beneficiaries, totaling 812,881 services with total Medicare billing of $10.2M. Data is available for 4 years (2020–2023), covering 289 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Fort Myers, FL
- Active Since 11/23/2005
- Last Updated 08/06/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1316920259
Products in Payments
- Abraxane (Drug) $29,900
- TECENTRIQ (Biological) $7,836
- OPDIVO (Biological) $1,548
- KEYTRUDA (Biological) $1,427
- Lenvima (Drug) $789.65
- Cabometyx (Drug) $526.49
- DARZALEX (Biological) $493.26
- JAKAFI (Drug) $490.14
- BRUKINSA (Drug) $452.05
- REBLOZYL (Biological) $432.64
- KISQALI (Drug) $419.09
- TASIGNA (Drug) $398.40
- IMBRUVICA (Drug) $392.26
- PADCEV (Biological) $357.33
- MONJUVI (Drug) $355.32
- PROMACTA (Drug) $349.48
- CYRAMZA (Drug) $341.94
- Rubraca (Drug) $341.40
- CALQUENCE (Drug) $332.57
- ZEPZELCA (Drug) $328.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Fort Myers
Dr. Lowell Hart, M.d, M.D
Medical Oncology — Payments: $402,512
Medical Oncology $402,512
Dr. James Reeves, M.d, M.D
Medical Oncology — Payments: $198,428
Medical Oncology $198,428
Dr. Vitor Pastorini Filho, M.d, M.D
Medical Oncology — Payments: $18,036
Medical Oncology $18,036
Dr. Van Rana, 09221980, 09221980
Medical Oncology — Payments: $9,740
Medical Oncology $9,740
Venkata Parsa, Md, MD
Medical Oncology — Payments: $1,888
Medical Oncology $1,888
Dr. Manoel Moraes, Md, MD
Medical Oncology — Payments: $1,670
Medical Oncology $1,670